

FALSE-POSITIVE HIV TEST RESULTS: DIAGNOSTIC CHALLENGES AND PRE-TEST PROTOCOLS

Tolqinboyev Komiljon

Andijan Regional Center for the fight against AIDS, doctor epidemiologist

Relevance: HIV remains one of the most significant public health challenges globally, particularly in developing regions where diagnostic capacity and public awareness vary widely. In Uzbekistan, ongoing public health initiatives are directed toward early diagnosis and treatment of HIV, as mandated by recent governmental orders (Order No. 111, 2023; Order No. 270, 2023). However, false-positive HIV test results, although statistically rare, continue to cause considerable psychological distress, unnecessary medical interventions, and social complications for affected individuals.

This issue becomes especially critical in populations with low HIV prevalence, where the likelihood of a false-positive result may outweigh the probability of true infection. The phenomenon is notably common among pregnant women, due to physiological changes that may trigger antibody cross-reactivity. Despite the existence of advanced diagnostic algorithms, the persistence of false-positive outcomes indicates a need to strengthen test protocols, patient counseling, and post-test procedures.

Given the potential for harm resulting from misdiagnosis—including unnecessary antiretroviral therapy and social stigmatization—this study seeks to highlight the importance of accurate HIV testing. It also aims to contribute to the body of knowledge that supports improved pre-test preparation, testing algorithms, and quality control systems in healthcare settings.

Keywords: HIV diagnosis; false positive; immunoassay; confirmatory testing; antiretroviral therapy; pregnancy; public health

INTRODUCTION

HIV screening programs are expanding worldwide, but even high-quality tests can yield rare false-positive results (a reactive result in an uninfected person). In Uzbekistan, recent Ministry of Health directives (e.g. Order No.111 of 19 May 2023) have reinforced the need for robust HIV testing and prevention protocols. A false-positive HIV result is alarming for patients and providers alike: it can provoke significant emotional and social distress. Because such an error may lead to unnecessary treatment and stigma, testing guidelines always require confirmatory assays after any reactive screen. This paper reviews common HIV diagnostic methods, examines published data on false-positive rates and risk factors (including pregnancy), and discusses the impacts of misdiagnosis. We also outline best practices for pre-test counseling and repeat testing to ensure accurate HIV diagnosis.

METHODS

HIV infection is typically diagnosed using a multi-step algorithm combining screening and confirmatory assays. Key methods include: mandated for any initial positive screen. This multi-test strategy is central to minimizing misdiagnosis.

RESULTS

Published data show that false-positive HIV diagnoses are uncommon but not negligible. Key findings from the literature include:

Test performance: Approved HIV tests have very high specificity (~99.6%). Statistically, this implies that about 4 in 1,000 uninfected individuals may receive a false-reactive result. Large field studies confirm low error rates. For example, one cohort study in Mozambique reported a cumulative false-

diagnosis rate of only ~0.56%. (A systematic review noted a higher median rate of 3.1% across diverse studies, but improved algorithms and retesting greatly reduce this in practice)

Pregnancy: Physiological changes in pregnancy have been linked to false-positive HIV screening. Maternally derived alloantibodies or immune shifts can cause an ELISA to react without true infection. In fact, “prior pregnancies” are explicitly listed as a factor that may trigger a false-reactive HIV test. Several case reports confirm that pregnant women occasionally have false-positive screens, causing undue anxiety and follow-up.

Other medical conditions: Cross-reactive antibodies from other sources can cause false positives. Known associations include recent viral infections (e.g. Epstein–Barr virus), autoimmune disorders (e.g. lupus, rheumatoid arthritis), and other infections such as syphilis or Lyme disease. For instance, syphilis antibodies can be misrecognized by HIV assays. Likewise, recent immunizations (e.g. influenza or hepatitis B vaccines) and even blood transfusions have been associated with transient false-positive HIV results.

Statistical context: False-reactive results are more likely when HIV prevalence is low. In a low-prevalence setting, even a test with 99% specificity may yield more false positives than true positives. Thus clinical context and confirmatory testing are crucial.

These data underscore that while false-positive HIV results are rare in absolute terms, they are a recognized clinical issue. The table below summarizes typical error rates and contributing factors: Assay specificity: ~99.6% (~ 0.4% false-positive rate). Observed false-diagnosis rate: ~0.1–0.5% in large studies. **Pregnancy risk:** Pregnancy/alloantibodies known to elevate false positives. **Autoimmune/other:** Lupus, rheumatoid arthritis, EBV, syphilis can cause cross-reactions. **Vaccination/transfusion:** Recent flu/hepB vaccine or transfusion (rarely) can transiently affect results.

DISCUSSION

False-positive HIV results have serious individual and public-health consequences. Misdiagnosis can lead to inappropriate treatment, marital discord, and loss of trust in health services. As one analysis notes, “false-positive HIV diagnosis can result in severe individual and public health consequences, including separation from spouse and family, unnecessary care and treatment, and public distrust in HIV testing”. Case reports document patients developing depression, relationship strain, and even considering suicide after a false-positive result, even if corrected later. Medico-legal issues can also arise if counseling and consent are inadequate.

To mitigate these outcomes, best practices center on rigorous testing protocols and patient preparation. Key recommendations include:

Pre-test counseling: Patients should be informed about the HIV testing process, including the possibility of a reactive preliminary result and the need for confirmatory tests. Ethical guidelines emphasize obtaining informed consent and providing information on the “window period” and test limitations. Proper counseling helps patients understand that a reactive screen is not an immediate diagnosis.

Confirmatory testing algorithm: Adhere strictly to national/WHO protocols, which require at least two sequential reactive tests (of different types) before a positive diagnosis is made. For example, a fourth-generation ELISA reactive result should be followed by an immunoblot or a second rapid assay. Only when multiple independent assays agree is an HIV diagnosis confirmed. This algorithmic approach – often called the testing “cascade” or “sequence” – is designed to catch false-positives before disclosure. **Retesting and quality assurance:** Consistent with WHO guidelines, any patient with an initial positive result should be retested on a fresh specimen before starting antiretroviral therapy. Laboratory quality management systems (kit controls, double-reading, proficiency testing) are also essential. Studies have shown that reinforcing quality assurance and re-testing can reduce false diagnoses dramatically.

Psychosocial support: If a result is initially reactive, provide immediate counseling to address anxiety. Upon receiving confirmatory testing, patients should be given psychological support and the correct information. One study noted that after correcting false-positive diagnoses, patients felt “relief” but needed reassurance. Engaging counselors or psychologists as needed can mitigate the emotional impact.

By combining thorough pre-test preparation (informing clients and obtaining consent) with strict adherence to multi-step testing and retesting, healthcare providers can uphold diagnostic accuracy and minimize the harm of false-positive HIV results.

Conclusion

False-positive HIV test results, while infrequent, pose significant diagnostic and psychosocial challenges. Ensuring accuracy requires a robust testing algorithm and careful patient preparation. Current evidence and guidelines underline that no single reactive test is definitive – every positive screen must be confirmed with additional assays. With specificity already >99%, routine retesting and quality control can drive false-positive rates essentially to zero in practice. Crucially, comprehensive counseling before and after testing helps patients understand the process and cope with uncertainty. In sum, strict adherence to standardized testing protocols, combined with ethical pre-test preparation, protects patients from the consequences of erroneous HIV diagnoses and improves overall care quality.

References:

1. Ministry of Health of the Republic of Uzbekistan. (2023, May 19). Order No. 111: On further improvement of the organization of medical care and measures for prevention of HIV infection in the Republic of Uzbekistan. Tashkent, Uzbekistan.
2. Ministry of Health of the Republic of Uzbekistan. (2023, October 31). Order No. 270: On protocols of prevention and treatment of HIV infection. Tashkent, Uzbekistan.
3. Murodqasimov, S. (n.d.). Etiology, epidemiology and prevention of HIV infection. Samarkand: Samarkand State Medical Institute.
4. Johnson, C., Fonner, V., Sands, A., Ford, N., Obermeyer, C. M., Tsui, S., & Baggaley, R. (2015). To err is human: WHO guidance on HIV testing and misdiagnosis. *Journal of the International AIDS Society*, 18(1), 20205. <https://doi.org/10.7448/IAS.18.1.20205>
5. Mwau, M., Syeunda, C. A., Adhiambo, M., Mbugua, J., Moore, D., & Graham, S. M. (2021). False-positive HIV diagnosis in sub-Saharan Africa: Systematic review and meta-analysis of 29 studies. *The Lancet Global Health*, 9(5), e706–e718. [https://doi.org/10.1016/S2214-109X\(21\)00047-2](https://doi.org/10.1016/S2214-109X(21)00047-2)
6. Delaney, K. P., Branson, B. M., Uniyal, A., Kerndt, P. R., Keenan, P. A., Jafa, K., ... & Owen, S. M. (2011). Evaluation of the performance characteristics of 6 rapid HIV antibody tests. *Clinical Infectious Diseases*, 52(2), 257–263. <https://doi.org/10.1093/cid/ciq068>
7. Galli, R. A., Green, L., & Sloand, E. (2012). HIV testing: Improving the accuracy and reliability of results. *The Nurse Practitioner*, 37(4), 38–45. <https://doi.org/10.1097/01.NPR.0000412253.08792.d5>
8. World Health Organization. (2015). Consolidated guidelines on HIV testing services 2015. Geneva: WHO Press. <https://apps.who.int/iris/handle/10665/179870>
9. Centers for Disease Control and Prevention. (2014). Technical update on HIV testing algorithms. Atlanta, GA: U.S. Department of Health and Human Services.